Endothelin antagonists for hypertension and renal disease

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 5, 1999, Pages 549-556

  Barton, Matthias ^a   Luscher, Thomas F ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; DRUG USE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

AMINO ACID SEQUENCE; ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; ENDOTHELIN-1; ENDOTHELINS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; HYPERTROPHY; KIDNEY DISEASES; MOLECULAR SEQUENCE DATA; RATS; RECEPTORS, ENDOTHELIN;

EID: 0033404490     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199909000-00003     Document Type: Review

References (89)

1. 1 Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248:C550-C556.
2. 2 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
3. 3 Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269:10112-10118.
4. 4 Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96:1059-1065.
5. 5 Barton M, Shaw S, d'Uscio LV, Moreau P, Lüscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA-receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238:861-865.
6. 6 Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993; 92:398-403.
7. 7 Iwasaki S, Homma T, Matsuda Y, Kon V. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 1995; 270:6997-7003.
8. 8 Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61:391-415. Excellent up-to-date review of the molecular actions and pathophysiologic significance of endothelin in cardiovascular disease.
9. 9 Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86:2863-2867.
10. 10 Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression and biological activity. J Biol Chem 1989; 264:14613-14616.
11. 11 Bloch KD, Hong CC, Eddy RL, Shows TB, Quertermous T. cDNA cloning and chromosomal assignment of the endothelin-2 gene: vasoactive intestinal contractor peptide is rat endothelin-2. Genomics 1991; 10:236-242.
12. 12 Kishi F, Minami K, Okishima N, Murakami M, Mori S, Yano M, et al. Novel 31-amino acid-length endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun 1998; 248:387-390.
13. 13 Malek A, Izumo S. Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol 1992; 263:C389-396.
14. 14 Wesson De, Simoni J, Green DF. Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J Clin Invest 1998; 101:578-583. Interesting report demonstrating a role of pH as a regulator of endothelin release with important clinical implications on acid-base disturbances.
15. 15 Matsuura A, Yamochi W, Hirata K, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998; 32:89-95.
16. 16 Corder R, Carrier M, Khan N, Klemm P, Vane JR. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. J Cardiovasc Pharmacol 1995.
17. 17 Schwarting A, Schlaak J, Lotz J, Pfers I, Meyer BK, Mayer W. Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). Scand J Rheumatol 1996; 25:246-256.
18. 18 Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587-590.
19. 19 Stewart D, Cernacek P, Mohamed F, Blais D, Cianflone K, Monge JC. Role of cyclic nucleotides in the regulation of endothelin-1 production by human endothelial cells. Am J Physiol 1994; 266:H944-H951.
20. 20 Wada A, Tsutamato T, Maeda Y, Kanamori T, Matsuda Y, Kinoshita M. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol 1996.
21. 21 Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, Levin ER. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 1998; 330:1097-1105.
22. 22 Wypij DM, Nichols JS, Novak PJ, Stacy L, Berman J, Wiseman JS. Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992; 43:845-853.
23. 23 Ikeda K, Emoto N, Matsuura A, Raharjo SB, Nurhantara Y, Alimsordjono H, Matsuo M. Molecular cloning and characterization of a novel metalloprotease that cleaves big-endothelin-1 to produce active endothelin-1 (abstract). Circulation 1998; 98:1-745.
24. 24 Hoang MV, Turner AJ. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 1998; 327:23-26. This study and the study of Johnson et al. [25] first demonstrated that endothelin converting enzyme is not selective for the conversion of big endothelin-1 but also inactivates bradykinin, substance P, and insulin.
25. 25 Johnson GD, Stevenson T, Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 1999; 274:4053-4058.
26. 26 Hasegawa H, Hiki K, Sawamura T, Aoyama T, Okamoto Y, Miwa S, Shimohama S, Kimura J, Masaki T. Purification of a novel endothelin-converting enzyme specific for big endothelin-3. FEBS Lett 1998; 428:394-398.
27. 27 Hofman FM, Chen P, Jeyaseelan R, Incardona F, Fisher M, Zidovetzki R. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood 1998; 92:3064-3072.
28. 28 Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 242:202-208.
29. 29 Hafizi S, Wharton J, Chester AH, Polak JM, Jacoub MH. Endothelin-1 stimulates collagen synthesis in cultured human cardiac fibroblasts via the ETA receptor (abstract). Circulation 1998; 98:1-79.
30. 30 Marini M, Carpi S, Bellini A, Patalano F, Mattoli S. Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun 1996; 220:896-899.
31. 31 Weissberg PL, Witchel C, Davenport AP, Herketh TR, Metcalfe JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafatoxin S6c are comitogenic with platelet derived growth factor for vascular smooth muscte cells. Atherosclerosis 1990; 83:257-262.
32. 32 Pedram A, Razandi M, Hu RM, Levin ER. Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 1998; 273:13966-13972.
33. 33 Suzuki E, Nagata D, Kakoki M, Hayakawa H, Goto A, Omata M, Hirata Y. Molecular mechanisms of endothelin-1-induced cell-cycle progression. Involvement of extracellular signal-regulated kinase, protein kinase C, and phosphatidylinositol e-kinase at distinct points. Circ Res 1999; 84:611-619. This study demonstrated the involvement of kinases as downstream mediators of endothelin-1-induced progression of the cell cycle.
34. 34 Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995;235-255.
35. 35 Goto K, Kasuya Y, Matsuki N, Takuwa Y, Kurihara H, Ishikawa T, et al. Endothelin activates the dihydropyridine-sensitive voltage-dependent Ca(2+) channel in vascular smooth muscle. Proc Natl Acad Sci U S A 1989; 86:3915-3918.
36. 36 Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 1989; 13:S85-S88.
37. 37 Hirata Y, Emori T, Eguichi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91:1367-1372.
38. B-receptor mediated autocrine regulation of the endothelium-derived vasodilator adrenomedullin.
39. 39 Shichiri M, Kato M, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine spoptosis survival factor for endothelial cells. Hypertension 1997; 30:1198-1203.
40. 40 Naomi S, Iwaoka T, Disashi T, Inoue J, Kanesaka Y, Tokunaga H, Tomita K. Endothelin-1 inhibits endothelin-converting enzyme-1 expression in cultured rat pulmonary endothelial cells. Circulation 1998; 97:234-236.
41. 41 Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199:1461-1465.
42. 42 Iwasaki T, Notoya M, Hayasaki-Kajiwara Y, Shimaramura T, Naya N, Ninomiya M, Nakajima M. Endothelium-independent vascular relaxation mediating ETB receptor in rabbit mesenteric arteries. Am J Physiol 1999; 276:H383-H390. First study providing evidence for an endothelium-independent component of ETB-mediated vasodilatation involving prostanoids.
43. B receptors in humans.
44. 44 Ohuchi T, Kuwaki T, Ling GY, Dewit D, KH J, Onedora M, et al. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 1999; 276:R1071-R1077.
45. 45 Lüscher TF, Vanhourte PM. The endothelium: modulator of cardiovascular function. 1990; CRC Press, Boca Raton, USA; 1-215.
46. 46 Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996; 71:769-777.
47. 47 d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Lüscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997; 29:435-441.
48. 48 Barton M, d'Uscio L, Shaw S, Meyer P, Moreau P, Lüscher TF. ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;499-504.
49. 49 Best BJ, McKenna CJ, Hasdai D, Holmes DR Jr, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999; 99:1747-1752.
50. 50 Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Münter K, Lüscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoE-deficient mice. Proc Natl Acad Sci U S A 1998; 95:14367-14372.
51. 51 Prie S, Stewart DJ, Dupuis J. EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation 1998; 97:169-174.
52. A blockade may increase nitric oxide production.
53. 53 Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87:1475-1481.
54. 54 d'Uscio LV, Shaw S, Moreau P, Barton M, Lüscher TF. Blood pressure independent effects of chronic selective ETA-receptor blockade in L-NAME-induced hypertension. J Hypertens 1998; 16 (suppl. 2):S90.
55. 55 Moreau P, Takase H, Kung CF, Shaw S, Lüscher TF. Blood pressure and vascular effects of endothelin blockade in chronic nitric-oxide deficient hypertension. Hypertension 1997; 29:763-769.
56. 56 Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.
57. 57 Lüscher TF, Seo BG, Bühler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993; 21:752-757.
58. 58 Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-185.
59. 59 Moreau P, d'Uscio LV, Takase H, Shaw S, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-antagonist. Circulation 1997; 96:1593-1597.
60. 60 Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin antagonist. Hypertension 1995; 25:495-500.
61. 61 Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996; 271:H88-H93.
62. 62 Moreau P. Endothelin in hypertension: a role for receptor antagonists? Cardiovasc Pharmacol 1998; 38:534-542.
63. 63 Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Enhanced expression of endothelin-1 gene may cause blood pressure-independent vascular hypertrophy. J Cardiovasc Pharmacol 1995; 26:S5-S8.
64. 64 Hocher B, Thöne-Reinecke C, Rohmeiss P, Schmager F, Slowinski R, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99:1380-1390.
65. B receptor.
66. 66 Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlton V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338:784-790. First clinical trial of endothelin antagonism in hypertension showing similar blood pressure lowering effects as the ACE inhibitor enalapril. Further clinical testing of the drug has been stopped due to marked hepatic side effects of bosentan.
67. 67 Yang Z, Naziri G, Lüscher TF. Endothelin-1 markedly potentiates the proliferative effect of platelet-derived growth factor. Circulation 1999; 100: 5-8.
68. 68 Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78:225-228.
69. 69 Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998; (suppl) 16:S3-S8.
70. 70 Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15:57-63.
71. 71 Schiffrin EL, Lariviere R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res 1996; 33:235-248.
72. 72 Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Endothelin-1 gene expression and vascular hypertrophy in DOCA-salt hypertension compared to spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995; 22:5188-8190.
73. 73 Verhagen AM, Rabelink TJ, Braam B, Ogenorth TJ, Grone HJ, Koomans HA, Joles JA. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitrix oxide synthase inhibition. J Am Soc Nephrol 1998; 9:755-762.
74. 74 Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 1998; 31:995-1001.
75. 75 Rossi GP, Colonna S, Pavan E, Albertin G, Della Rocca F, Gerosa G, Casarotto D, Sartore S, Pauletto P, Pessina AC. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 1999; 99:1147-1155. This study provides unequivocal evidence that components of the endothelin system including ECE, and endothelin mRNA and proteins are increased both in the endothelium as well as in the vascular smooth muscle in patients with hypertension and atherosclerosis.
76. 76 Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 1999; 33:759-765.
77. 77 Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29:2-26.
78. 78 Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-444.
79. 79 Forbes JM, Leaker B, Hewitson TD, Becker GJ, Jones CL. Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int 1999; 55:198-208.
80. 80 Begnini A, Remuzzi G. The renoprotective potential of endothelin receptor antagonists. Exp Opin Ther Patents 1997; 7:139-149.
81. 81 Rabelink TJ, Koomans HA. Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs 1997; 53 (suppl. 1):11-19.
82. A-receptor antagonism inhibits transplant vasculopathy and glomerular injury independently from immunosuppression in rats.
83. 83 Baylis C. Age-dependent glomerular damage in the rat. J Clin Invest 1994; 94:1823-1829.
84. 84 Barton M, Lattmann T, Shaw S, Lüscher TF. Aging, a cardiovascular risk factor, markedly increases expression of endothelin-1 in vivo independent of blood pressure and endothelin-1 clearance. J Am Coll Cardiol 1999; 33 (suppl. A):225.
85. 85 Benigni A, Zola C, Corna D, Orisio S, Facchinetti D, Benati L, Remuzzi G. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996; 27:416-423.
86. 86 Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998; 31:397-402.
87. 87 Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998; 31:10-14.
88. 88 Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, Joles JA. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension 1999; 33:137-144.
89. 89 Barton M, d'Uscio LV, Shaw S, Vos I, Rabelink T, Lattman T, Lüscher F. Dysfunctional renal nitric oxide synthase and increased endothelin-1 in Dahl salt-sensitive hypertension. Modulation by chronic ETA receptor blockade. Hypertension 1998; 32:623.